Gilead Sciences, Inc. [NASDAQ: GILD] traded at a low on Monday, posting a -0.32 loss after which it closed the day’ session at $76.71. The company report on February 1, 2024 at 4:31 PM that Ted Love, MD, Joins Gilead Sciences’ Board of Directors.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors.
Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. where he led the company from a pre-clinical startup to a global commercial company with a focus on sickle cell disease. Prior, he was Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc.; President, Chief Executive Officer and Chairman of Nuvelo, Inc.; and Senior Vice President, Development at Theravance Biopharma, Inc. He began his biotech career at Genentech. Dr. Love earned his MD from the Yale School of Medicine and completed a residency in Internal Medicine and a fellowship in cardiology at Massachusetts General Hospital.
The results of the trading session contributed to over 6541580 shares changing hands. Over the past one week, the price volatility of Gilead Sciences, Inc. stands at 1.36% while the volatility over the past one month is 1.75%.
The market cap for GILD stock reached $95.58 billion, with 1.25 billion shares outstanding and 1.24 billion shares in the current float. Compared to the average trading volume of 7.02M shares, GILD reached a trading volume of 6541580 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Gilead Sciences, Inc. [GILD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $89.32 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.19. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for Gilead Sciences, Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 09, 2023.
The Average True Range (ATR) for Gilead Sciences, Inc. is set at 1.62, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.51. The Price to Book ratio for the last quarter was 4.29, with the Price to Cash per share for the same quarter was set at 6.40. Price to Free Cash Flow for GILD in the course of the last twelve months was 12.17 with Quick ratio for the last quarter at 1.20.
How has GILD stock performed recently?
Gilead Sciences, Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.98. With this latest performance, GILD shares dropped by -9.20% in over the last four-week period, additionally sinking by -2.50% over the last 6 months – not to mention a drop of -5.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 34.65, with the RSI for the last a single of trading hit 26.92, and the three-weeks RSI is set at 39.68 for Gilead Sciences, Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 80.41, while it was recorded at 77.74 for the last single week of trading, and 78.34 for the last 200 days.
Gilead Sciences, Inc. [GILD]: Deeper insight into the fundamentals
Gilead Sciences, Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.34.
Earnings analysis for Gilead Sciences, Inc. [GILD]
With the latest financial reports released by the company, Gilead Sciences, Inc. posted 1.67/share EPS, while the average EPS was predicted by analysts to be reported at 1.49/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences, Inc. go to 4.21%.
Insider trade positions for Gilead Sciences, Inc. [GILD]
The top three institutional holders of GILD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in GILD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in GILD stock with ownership which is approximately 5.8325%.
